Jame Abraham, Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared ACS Cancer Journal’s post on X, adding:
“This is a very interesting concept – not all progression is equal – not all stage IV is the same …we need to continue to understand the nuances of individual variations in cancer so that we don’t treat all cancers the same way!”
Quoting ACS Cancer Journal’s post on X:
“Oncology clinical trials have long relied on RECIST criteria to define progression. In this new commentary, MSK Cancer Center
researchers propose further study and reporting of how treatment failure is characterized.”
Other OncoDaily articles featuring Jame Abraham.